GlassScriptPhysician profile
Tania Vora
NPI 1265758122
$14,624.75
in general payments reported to CMS, 2019-2025
17 companies · $4,801 in 2025
The $4,801 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.10 · 2022: $536 · 2023: $8,632 · 2024: $633 · 2025: $4,801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,927 · Consulting Fee: $3,984 · Food and Beverage: $3,455 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,927.28 |
| Consulting Fee | $3,984.00 |
| Food and Beverage | $3,454.54 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,700.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $12,030.81 | 2022-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, 2nd Gen Centrimag Primary Console |
| Bridgebio Pharma, INC. | $1,494.08 | 2025 | Attruby |
| Abiomed | $379.59 | 2022-2024 | Impella |
| Novo Nordisk INC | $142.68 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $108.02 | 2023-2024 | Farxiga, Wainua |
| Cvrx, INC. | $85.54 | 2024-2025 | Barostim Neo System |
| Kestra Medical Technology Services, INC. | $62.38 | 2025 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $60.63 | 2023-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $49.97 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $45.96 | 2023-2024 | Inpefa |
| E.R. Squibb & Sons, L.L.C. | $36.19 | 2023 | Camzyos |
| Atricure, INC. | $32.39 | 2024 | |
| Medtronic Vascular, INC. | $23.10 | 2019 | |
| Cardiac Dimensions, INC. | $19.25 | 2025 | |
| Scpharmaceuticals INC. | $18.53 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $18.47 | 2024 | Xarelto |
| Merck Sharp & Dohme LLC | $17.16 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tania Vora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.